22 peptides tracked
Australia's
Independent
Peptide Register
No vendors. No affiliates. Just data.
Fig. 01
Regulatory Status · October 2026
Retatrutide2
GHK-Cu10
Semaglutide12
Tirzepatide8
BPC-15718
CJC-129515
22
Peptides tracked
40
Prescription providers
52
Observed suppliers
1
Prohibited (S9)
01Intelligence
Peptide Status
TGA scheduling, enforcement trends, and access pathways for each peptide. Updated October 2026.
Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.
Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
GHK-Cu
Copper Peptide
Semaglutide
GLP-1 Agonist
Tirzepatide
GLP-1/GIP Agonist
BPC-157
Tissue Repair
CJC-1295
Growth Hormone Secretagogue
Ipamorelin
Growth Hormone Secretagogue
TB-500
Tissue Repair
Melanotan II
Melanocortin Agonist
PT-141 (Bremelanotide)
Melanocortin Agonist
MOTS-c
Mitochondrial Peptide
Thymosin Alpha-1
Immune Modulator
KPV
Anti-inflammatory Peptide
Epithalon
Telomerase Activator
Gonadorelin
Hormonal Support
Dihexa
Cognitive Enhancement
02News
Regulatory Feed
Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.
HeadlineSourceDate
The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.Semaglutide
Expert review of clinical immunology8 Oct 2026Ischemic colitis associated with oral semaglutide with recurrence upon rechallenge.Semaglutide
Revista espanola de enfermedades digestivas8 Oct 2026Beyond body mass index: A contemporary review of obesity and female infertility.Tirzepatide
Clinical and experimental reproductive medicine8 Oct 2026Navigating Electroconvulsive Therapy in Patients on GLP-1 Receptor Agonists: Balancing Safety, Compliance, and Treatment Consistency: A Case Report.Tirzepatide
The journal of ECT8 Oct 2026Effects of a GLP-1 agonist and anti-diabetic therapies on pheochromocytoma/paraganglioma growth.Semaglutide
Endocrine-related cancer7 Oct 2026The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment.Semaglutide
Obesity (Silver Spring, Md.)7 Oct 2026Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625-632).Tirzepatide
Ophthalmology. Retina7 Oct 2026Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical Insights.Tirzepatide
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology7 Oct 2026Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.Retatrutide
BMJ case reports7 Oct 2026Correction to: Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.Semaglutide
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology6 Oct 2026Medicaid's GLP-1 Coverage Gap: A Familiar and Correctable Policy Failure.Semaglutide
Medical care6 Oct 2026GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials.Tirzepatide
Sleep & breathing = Schlaf & Atmung6 Oct 2026Annals On Call - Tirzepatide Versus Intensified Conventional Care for Poorly Controlled Type 2 Diabetes.Tirzepatide
Annals of internal medicine6 Oct 2026In brief: A cardiovascular indication for tirzepatide (Mounjaro).Semaglutide
The Medical letter on drugs and therapeutics5 Oct 2026Practical Considerations for the Use of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity: A Clinician-Oriented Guide.Semaglutide
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir5 Oct 2026Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries.Tirzepatide
Peptides5 Oct 2026Biologic Injection-Related Pain in Severe Asthma, Its Impact on Treatment Aversion, and Pain-Relief Approach: A Multicenter Observational Study.Tirzepatide
The journal of allergy and clinical immunology. In practice5 Oct 2026Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetesSemaglutide
J Diabetes Metab Disord5 Oct 2026Quantifying Medicare prescription payment plan benefits under Medicare Part D.Semaglutide
Journal of the American Pharmacists Association : JAPhA3 Oct 2026Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study.Semaglutide
Journal of the European Academy of Dermatology and Venereology : JEADV3 Oct 2026Regulatory Notice
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.